‘Like a spelling mistake’: B.C. teen’s DNA ‘corrected’ to cure rare disease

Dr. Stuart Turvey said there have been other treatments for chronic granulomatous disease, involving hematopoietic stem cell ...

B.C. man cured of rare disease in world-first for new gene-editing technology

Ty Sperle says he felt "insane shock" after learning he'd been cured of a rare genetic disease through a clinical trial using ...

Patient from Kelowna first to be cured of rare immune disease

An 18-year-old from Kelowna is the first person with CGD to receive and be cured by a gene modification treatment known as ...
Canada's National Observer

BC man is cured of rare disease in world-first for new gene-editing technology

Ty Sperle says he felt "insane shock" after learning he'd been cured of a rare genetic disease through a clinical trial using ...

B.C. teen first in world to be cured of rare disease through gene editing treatment

It is really crazy to think about,' says 18-year-old Ty Sperle. 'We're definitely at a turning point in medicine' ...
The Washington Post

Scientists finally may know why kidney patients die of heart disease

For years, scientists have been working to unravel the mystery of patients with failing kidneys dying from heart-related complications. Researchers now say they’ve uncovered a clue that explains why ...
Cleveland.com

Chronic disease could cost US $47 trillion by 2039, new report finds

CLEVELAND, Ohio — Chronic disease could cost the United States as much as $47 trillion between 2024 and 2039, including $2.2 trillion annually in medical costs and nearly $900 billion each year in ...
Seeking Alpha

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, ...
precisionmedicineonline

Ensoma Doses First Patient in Immune Disorder Gene Therapy Trial

NEW YORK – Ensoma on Monday said it dosed the first patient in a Phase I/II trial of EN-374, an investigational gene therapy for X-linked chronic granulomatous disease (X-CGD). EN-374 is an in vivo ...
Morningstar

Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD

First ever clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function for people living with X-linked chronic granulomatous disease Ensoma, an in vivo ...